Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06318936
Other study ID # 22-677
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date November 1, 2022
Est. completion date May 1, 2024

Study information

Verified date March 2024
Source UMC Utrecht
Contact Joanne G Wildenbeest, MD, PhD
Phone 0031887563776
Email J.G.Wildenbeest@umcutrecht.nl
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

RSV infection is a leading cause of medical care in older adults, sometimes leading to hospital admission and severe outcomes. Although the majority of RSV infections are managed outside hospitals, little is known on the burden of RSV in older adults in the primary care setting. Accurate estimates of the RSV burden in primary care is particularly relevant since vaccines against RSV infection in older adults will likely become available for the general population soon. The use of high-quality point-of-care (POC) molecular viral diagnostics allows to identify RSV infected older adults and would therefore contribute to fill one of the most important gaps in knowledge facilitating implementation of RSV vaccination of older adults With this prospective, observational study, we aim to define the disease burden of RSV infection in older adults in the primary care setting.


Description:

Th RAPID study is a prospective, observational study in Dutch primary care practices during two RSV seasons. As part of routine care, rapid molecular viral diagnostic testing on respiratory samples will be offered to all older adults attending the primary care physician because of symptoms of acute respiratory tract infection (ARTI). RSV positive cases will be included for further study. Participants will be asked to fill out three questionnaires by phone or by online at day 0, 14 and 30 after the GP-visit. The main endpoint is the burden of medically attended RSV infection in the Dutch primary care setting, quantified using several clinical and socioeconomic parameters, including (but not limited to) clinical symptoms and their duration, medicine use, hospitalisation rate, quality of life and ability to perform normal daily activities. Secondary, data on health care consumption and indirect costs will be collected and we will assess the effect of age and severe comorbidity on clinical course of RSV disease. A population size of 1000 older adults age >60 years presenting with acute respiratory symptoms to the general practitioner (GP) during RSV season will be tested for RSV as part of routine care. We expect about 100 RSV+. Based on our sample size calculation, 100 RSV+ cases would provide sufficient accuracy for estimating the relevant outcomes.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date May 1, 2024
Est. primary completion date May 1, 2024
Accepts healthy volunteers No
Gender All
Age group 60 Years and older
Eligibility Inclusion Criteria: - Age (=60 years of age) - RSV positive - Subject is willing and able to give informed consent for participation in the study - Subject is willing and able to adhere to protocol-specific procedures Exclusion Criteria: - Subject is not able to understand and communicate in the local language or English. - Previous or current participation in RSV interventional trial (vaccine, antivirals)

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Netherlands University Medical Center Utrecht Utrecht

Sponsors (2)

Lead Sponsor Collaborator
UMC Utrecht Janssen-Cilag B.V.

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Burden of medically attended RSV infection in the Dutch primary care The burden of medically attended RSV infection in the Dutch primary care setting will be defined as severity and duration of clinical symptoms, and healthcare resource use. Data will be collected at three timepoints (Day 0, Day 14 and Day 30 days after viral swab)
Secondary RSV-related health care consumption and indirect costs in older adults Health care utilization will be calculated as the number of contact moments (including phone contacts, telemedicine and visits) with the GP-practices and other health-care providers (e.g. visit to specialist, emergency department). For hospitalized adults, the number of admitted days and the level of care (general ward, high dependency unit, intensive care unit) will be calculated.
Medical costs and socio-economic costs will be calculated based on the questionnaires at day 0, 14 and day 30.
Data will be collected at three timepoints (Day 0, Day 14 and Day 30 days after viral swab)
Secondary Proportion of medically attended RSV infection amongst all medically attended acute respiratory infections in older adults in the primary care setting The proportion of RSV positive older adults will be calculated as the number of older adults who tested positive for RSV divided by the total number of older adults who visit the participating GP practices because of ARTIs and were tested for RSV. At day of sampling (Day 0)
Secondary Association between disease severity and several clinical and demographic parameters (e.g. age, cardiopulmonary comorbidity, smoking status, chronic immunosuppressive medication use) and RSV burden (by disease severity and healthcare usage) We will explore potential risk factors ((e.g. age, cardiopulmonary comorbidity, smoking status, polypharmacy, chronic immunosuppressive medication use) for severe RSV disease. Data will be collected at three timepoints (Day 0, Day 14 and Day 30 after viral swab)
Secondary Incidence of RSV-related secondary bacterial pneumonia events and antibiotic use Incidence will be calculated as the proportion of subjects that show RSV-associated secondary bacterial pneumonia events (defined as pneumonia within 21 days after RSV infection) and antibiotic use. Data will be collected at the last timepoint (30 days after viral swab)
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03698084 - RESCEU: Defining the Burden of RSV Disease
Recruiting NCT05550545 - Infant RSV Infections and Health-related Quality of Life of Families
Completed NCT05587478 - A Study of EDP-323 in Healthy Subjects Phase 1
Recruiting NCT06180993 - Evaluation of the Effectiveness and Impact of Nirsevimab Administered as Routine Immunization
Suspended NCT03909867 - Emission Patterns of Respiratory Syncytial Virus
Recruiting NCT06259487 - Coordinated Vaccination Against RSV and Influenza in Patients With Chronic Heart Failure and Its Impact on Prognosis. N/A
Not yet recruiting NCT04144816 - Predictors of Respiratory Syncytial Virus (RSV) Hospitalizations in Infants
Completed NCT01090557 - Exhaled Nitric Oxide in Respiratory Syncytial Virus (RSV) Bronchiolitis: a Pilot Study N/A
Terminated NCT01475305 - Intranasal Challenge of Healthy Adults With Respiratory Syncytial Virus (RSV) Phase 1
Not yet recruiting NCT05928507 - FINDER® Instrument and FINDER® FLU A/B, RSV, SARS-CoV-2 Test Clinical Evaluation Protocol
Completed NCT03062917 - Nasal and Bronchial Absorption Sampling in RSV Bronchiolitis N/A
Completed NCT03691623 - A Phase 2a Study to Evaluate EDP-938 in the Virus Challenge Model Phase 2
Completed NCT03387137 - Evaluating the Infectivity, Safety, and Immunogenicity of a Respiratory Syncytial Virus Vaccine (RSV 6120/∆NS2/1030s) in RSV-Seropositive Children and RSV-Seronegative Infants and Children Phase 1
Completed NCT05070975 - Severity of RSV Infections in Twins
Active, not recruiting NCT04938830 - Clesrovimab (MK-1654) in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease (MK-1654-007) Phase 3
Recruiting NCT05568706 - A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications. Phase 2
Completed NCT03755778 - Drug-Drug Interaction Study Between EDP-938, Itraconazole, Rifampin, and Quinidine in Healthy Subjects Phase 1
Completed NCT01483911 - ALX-0171 Phase I Study, Evaluating Single Ascending Dose and Multiple Dose in Healthy Male Volunteers Phase 1
Recruiting NCT06170242 - A Controlled Phase 2a Study to Evaluate the Efficacy of EDP-323 Against Respiratory Syncytial Virus Infection in a Virus Challenge Model Phase 2
Completed NCT03750383 - Drug-Drug Interaction Study Between EDP-938, Cyclosporine and Prednisone in Healthy Adult Subjects Phase 1